TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38174564
Drug: Control (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (discontinue all antihypertensive agents)
Study: 38174569
Drug: Asundexian 50
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian 50 mg daily
Study: 38175228
Drug: Adjuvant transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant transcranial direct current stimulation (tDCS) with intensive speech-language therapy for 3 weeks
Study: 38175228
Drug: Intensive speech-language
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive speech-language therapy for 3 weeks
Study: 38175251
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg phosphorus
Study: 38175448
Drug: sTK1 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTK1 activity at end of treatment visit
Study: 38175466
Drug: Cenegermin 20
Normalized name: CENEGERMIN 20 ug in 1 mL OPHTHALMIC SOLUTION/ DROPS [OXERVATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegermin 20 mcg/ml, 1 drop in the affected eye(s) 6 times/day for 8 weeks
Study: 38175488
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray administered in < 5 min after seizure start
Study: 38175488
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray administered in ≥ 5 min after seizure start
Study: 38175627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fractionated stereotactic radiotherapy or whole-brain radiotherapy with pyrotinib (400 mg, once daily) and capecitabine (1000 mg/m2, twice daily, on days 1-14 of each 21-day cycle)
Study: 38175669
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Endocrine Therapy (ET)
Study: 38175669
Drug: CDK4/6-inhibitors +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6-inhibitors + Endocrine Therapy (ET)
Study: 38175837
Drug: School-based mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based mass drug administration (MDA)
Study: 38176228
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT) involving antiplatelet agents, blood pressure control, and statins
Study: 38176782
Drug: Mavacamten 5
Normalized name: mavacamten 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 5 mg once daily
Study: 38176857
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Amantadine and TMS for 6 weeks
Study: 38176866
Drug: Oxygen-ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-ozone therapy 2-3 times a week for 6 weeks (maximum of 15 sessions) with oral antibiotic therapy
Study: 38176866
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic therapy prescribed at baseline
Study: 38176875
Drug: Exercise Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Therapy (ET) - 12-week rehabilitation programme
Study: 38176875
Drug: Extracorporeal Shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shockwave Therapy (ESWT) - four sessions with 1 week rest between sessions during 1 month
Study: 38177178
Drug: High aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High aspirin reaction unit (≥ 414)
Study: 38177509
Drug: Rebound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebound therapy
Study: 38177855
Drug: bidridistrogene xeboparvovec,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bidridistrogene xeboparvovec, an adeno-associated virus-based gene therapy
Study: 38178048
Drug: Treatment modalities
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modalities for SE
Study: 38178168
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and sufentanil in combination (P + S)
Study: 38178168
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and esketamine in combination (P + K)
Study: 38178168
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and lidocaine in combination (P + L)
Study: 38178223
Drug: Probiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bifidobacterium lactis BI040, B. longum BL020, Lactobacillus rhamnosus LR110, L. casei LC130, L. acidophilus LA120, 5 billion CFU total)
Study: 38178887
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for acute basilar artery occlusion (BAO)
Study: 38179936
Drug: Moderate low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Moderate low-dose radiotherapy, dosage and duration not available
Study: 38181433
Drug: BMMNC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMNC treatment
Study: 38181724
Drug: Levcromakalim (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levcromakalim (0.05 mg/ml infusion)
Study: 38181782
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose methotrexate (MTX) 1.5 g/m2 after 6 cycles of R-CHOP regimen; IT liposomal cytarabine administered on day 0 of cycles 2 to 5 of R-CHOP; contralateral testis radiotherapy (25-30 Gy) recommended.
Study: 38181795
Drug: serplulimab 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: serplulimab 4.5 mg/kg plus nab-paclitaxel and carboplatin
Study: 38182456
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) with tPA
Study: 38182456
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous thrombolysis (no IVT)
Study: 38182784
Drug: Magnesium-Ibogaine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-Ibogaine therapy
Study: 38182785
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg
Study: 38182785
Drug: Ripretinib 150
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib 150 mg
Study: 38183045
Drug: Neuromuscular joint-protective
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular joint-protective exercise therapy program
Study: 38183497
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg intravenous preoperatively)
Study: 38183497
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg in initial irrigation fluid)
Study: 38183525
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) fixed dosing regimen (n=168)
Study: 38183526
Drug: CTC 100
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC 100 mg (44 mg rac-tramadol hydrochloride/56 mg celecoxib; n=164)
Study: 38183526
Drug: CTC 150
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC 150 mg (66 mg rac-tramadol hydrochloride/84 mg celecoxib; n=160)
Study: 38183526
Drug: CTC 200
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC 200 mg (88 mg rac-tramadol hydrochloride/112 mg celecoxib; n=160)
Study: 38183526
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg four times daily (n=159)
Study: 38183526
Drug: Placebo four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo four times daily (n=83)
Study: 38183804
Drug: Sham Quasi-Desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham Quasi-Desensitization Therapy for Insomnia (DTI)
Study: 38184303
Drug: CMV-targeting T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-targeting T cell receptor-engineered T (CMV-TCR-T) cell therapy, administered in 1 to 3 doses.
Study: 38184414
Drug: Preclinical model
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preclinical model with anti-PD-1 antibody
Study: 38184559
Drug: Contextual factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contextual factors (e.g., COVID-19 pandemic)
Study: 38184582
Drug: SGLT-2i/GLP-1RA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGLT-2i/GLP-1RA combination therapy
Study: 38184633
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of smoking cessation interventions at outpatient OAT clinics, including weekly follow-up, a short behavioural intervention, and provision of nicotine replacement products.
Study: 38185589
Drug: Sintilimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab monotherapy
Study: 38185589
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus platinum-based chemotherapy
Study: 39536751
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus platinum-based chemotherapy
Study: 38185720
Drug: Treatment-naïve BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naïve BC patients
Study: 38186641
Drug: New long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: New long-acting insulin analog
Study: 38187149
Drug: Moderate-to-severe anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-severe anemia (Hb <11 g/dL for men and <10 g/dL for women)
Study: 38187149
Drug: No anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anemia (Hb ≥13 g/dL for men and ≥12 g/dL for women)
Study: 38187149
Drug: Mild anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild anemia (Hb 11-13 g/dL for men and 10-12 g/dL for women)
Study: 38187863
Drug: Telazorlimab 300
Normalized name: Telazorlimab
DrugBank: Telazorlimab (DB16374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telazorlimab 300 mg every 2 weeks (part 1)
Study: 38187863
Drug: Telazorlimab 600
Normalized name: Telazorlimab
DrugBank: Telazorlimab (DB16374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telazorlimab 600 mg every 2 weeks (part 2)
Study: 38188262
Drug: Vaccine counseling
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine counseling in ICU recovery clinics (ICU-RCs)
Study: 38188344
Drug: Local thermotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 minutes, twice daily, for 5 days
Study: 38188467
Drug: TQB2450 (1-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 (1-30 mg/kg, intravenous once every 3 weeks)
Study: 38188690
Drug: Leritrelvir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leritrelvir 400 mg TID for 5 days
Study: 38189125
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to community-based rehabilitation (physical, occupational, or speech therapy) at discharge
Study: 38189125
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to physical therapy
Study: 38189125
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to occupational therapy
Study: 38189125
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to speech therapy
Study: 38190077
Drug: PP1M (fixed-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP1M (fixed-dose, 50, 75, 100, or 150 mg eq.)
Study: 38190077
Drug: PP3M (fixed-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP3M (fixed-dose, 175, 263, 350, or 525 mg eq.)
Study: 38190136
Drug: Argatroban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (60 mg per day for 2 days, followed by 20 mg per day for 5 days) in addition to standard therapy (oral mono or dual antiplatelet therapy)
Study: 38190242
Drug: RE-PACT intervention
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: RE-PACT intervention (action planning, rapid clinical response, weekly SMS text messaging surveillance)
Study: 38190642
Drug: Lopinavir/Ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (LPV/r) oral solution
Study: 38191245
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment including reduction and fixation of the syndesmosis
Study: 38191245
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment with an orthosis
Study: 38191317
Drug: MedSUS app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MedSUS app (provides general information about medications)
Study: 38191436
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no treatment
Study: 38191436
Drug: Simplified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified treatment receiving 1 sachet of RUTF daily until WAZ ≥-3 for 2 visits
Study: 38191436
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment receiving RUTF according to WHZ category
Study: 38191449
Drug: L-carnitine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 1000 mg (3 tablets daily) for 6 weeks
Study: 38191449
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets daily) for 6 weeks
Study: 38191613
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy followed by four cycles of atezolizumab plus docetaxel, oxaliplatin and capecitabine
Study: 38192233
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg subcutaneously at weeks 0 and 4
Study: 38192233
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg subcutaneously every 12 weeks after week 12
Study: 38192592
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg every 28 days until progression or unacceptable toxicity
Study: 38193158
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 2 to 4 sessions
Study: 38194016
Drug: Serplulimab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab (0.3, 1.0, 3.0, and 10.0 mg/kg every 2 weeks in 28-day cycles for up to 2 years)
Study: 38194047
Drug: Dupilumab (200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (200/300 mg) every 4 weeks for 16 weeks
Study: 38194162
Drug: Efbemalenograstim alfa
Normalized name: efbemalenograstim alfa
DrugBank: Efbemalenograstim alfa (DB18704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efbemalenograstim alfa (80, 240, or 320 µg/kg for TC; 240 or 320 µg/kg for TAC)
Study: 38194231
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiation
Study: 38194231
Drug: Chemoradiation followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoradiation followed by consolidation chemotherapy
Study: 38194233
Drug: Curative-intent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative-intent therapy for colorectal cancer
Study: 38194233
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-General (rapid version) score increase
Study: 38194272
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (5 doses over 28 days)
Study: 38194616
Drug: Adjuvant Abemaciclib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Abemaciclib plus endocrine therapy
Study: 38194616
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (endocrine therapy alone)
Study: 38194692
Drug: Tisagenlecleucel infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel infusion (0.6 × 10^8-6 × 10^8 chimeric antigen receptor-positive viable T cells)
Study: 38195076
Drug: Concurrent tumor-treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent tumor-treating fields (TTFields) with radiation and temozolomide
Study: 38195076
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment after recurrence
Study: 38195322
Drug: Mosunetuzumab (intravenous)
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab (intravenous) - 1 mg on Day 1, 2 mg on Day 8, 60 mg on Day 15/Cycle 2 Day 1, and 30 mg from Cycle 3 Day 1 onwards for a median of eight 21-day cycles.
Study: 38195348
Drug: 150-mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg IV infusion of lefamulin
Study: 38195348
Drug: 600-mg oral
Normalized name: ubidecarenone 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg oral tablet of lefamulin
Study: 38195568
Drug: Dietary sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary sulfur amino acid restriction (SAAR) ~ 2 g/day
Study: 38195568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group ~ 5.6 g/day sulfur amino acids
Study: 38195600
Drug: HEARTS-aligned components
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEARTS-aligned components including training health workers, strengthening access to medications, risk-based management, team-based care, and electronic monitoring.
Study: 38196092
Drug: Smoking (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking (daily and occasional)
Study: 38196092
Drug: Tobacco use
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco use (daily, occasional, and snus)
Study: 38196286
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy
Study: 38702783
Drug: Mind-body intervention
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body intervention as an adjunct to MOUD
Study: 38196650
Drug: MOUD (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUD (standard treatment)
Study: 38196756
Drug: Polyphenol-enriched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-enriched treatment (PET) lettuce
Study: 38196889
Drug: Mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 300 mg every 4 weeks for 52 weeks
Study: 38196969
Drug: Treatment-as-usual (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (n = 47)
Study: 38197000
Drug: Sustained-release pregabalin
Normalized name: pregabalin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release pregabalin tablet (YHD1119), once-daily dosing.
Study: 38197040
Drug: Qualitative understanding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative understanding of experiences related to cancer cachexia (CC) through semi-structured interviews
Study: 38197040
Drug: Treatment recommendations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendations by oncologist for anorexia and weight loss
Study: 38197815
Drug: Repotrectinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repotrectinib (160 mg daily for 14 days, then 160 mg twice daily)
Study: 38197817
Drug: 500-mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg daily dose of calcium supplementation
Study: 38197817
Drug: 1500-mg daily
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500-mg daily dose of calcium supplementation
Study: 38197816
Drug: Acoramidis hydrochloride
Normalized name: acoramidis hydrochloride
DrugBank: Acoramidis (DB17999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoramidis hydrochloride at a dose of 800 mg twice daily
Study: 38197863
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration of antiretroviral therapy (ART)
Study: 38197938
Drug: Venetoclax and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax and azacitidine (Ven/Aza) maintenance therapy: Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 (42-day cycles × 8, or 28-day cycles × 12)
Study: 38197938
Drug: Venetoclax and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax and azacitidine (Ven/Aza) maintenance therapy
Study: 38198010
Drug: HRS-2261 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2261 (25, 100, 200, 400, 800, and 1200 mg)
Study: 38198010
Drug: HRS-2261 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2261 (50, 200, and 400 mg)
Study: 38198053
Drug: Proactive intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive intravitreal aflibercept (IVT-AFL) treatment regimens (fixed dosing or treat-and-extend)